Skip to site alert.
Skip to content
Back to top
Our innovative research focuses on four areas:
- Basic research
- Next-generation therapeutics
- HIV prevention-vaccine development
- Passive administration of neutralizing antibodies and microbicides
The Ho Lab is committed to finding scientific solutions to end the HIV/AIDS pandemic and using the techniques acquired in their decades of HIV research to the novel coronavirus SARS-CoV-2.
The Huang Lab devotes efforts to develop HIV vaccine and antibody-based strategies and long-acting antiretroviral drugs as pre-exposure prophylaxis to halt or slow the spread of AIDS.
Dr. Meyers’ lab addresses health inequity by accelerating translation of scientific discoveries into public health interventions accessible to marginalized populations, with a particular focus on HIV.
The focus of the Sabo Lab is to expand our understanding of cellular host factors and their interaction with specific infecting viral pathogens: HIV-1 and the human respiratory syncytial virus (HRSV).
The goal of the Sheng Lab is to use interdisciplinary approaches to understand the mechanisms of antibody maturation and disease etiology, and to find therapeutic targets for disease prevention.
The Tsuji Lab's research projects are applied and translational, seeking to further understanding of host immune system for development of effective vaccines against infectious diseases and cancer.
The focus of the Wu Lab is to elucidate the mechanisms by which the HIV-1 envelope glycoprotein elicits neutralizing antibody responses in humans and rhesus macaques for HIV-1 vaccine development.
The Yamashita Lab studies the biology of human immunodeficiency virus to elucidate the fundamental principles of viral replication and to develop novel drug design strategies.